Advanced Search

 

Study ID Status Title Patient Level Data
MAL40009 Completed An Open-Label, Uncontrolled Study to Evaluate the Safety and Efficacy of MALARONE (Atovaquone and Proguanil Hydrochloride) for Treatment of Acute Plasmodium falciparum Malaria in Thailand Using Tablets Manufactured in Canada
MAL40010 Completed A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Malarone (atovaquone and proguanil hydrochloride) for Malaria Prophylaxis in Non-Immune Colombian Soldiers.
MALA4001 Completed An Open Label Study to Determine the Safety and Efficacy of a Sequential Treatment Regimen of MALARONE (atovaquone/proguanil) Followed by Primaquine in the Treatment of Acute Plasmodium vivax Malaria in Adults
MALA4002 Completed An Open-Label Study to Determine the Efficacy and Safety of a Sequential Treatment Regimen of MALARONE (Atovaquone and Proguanil Hydrochloride) Followed by Primaquine for the Treatment of Acute Plasmodium Vivax Malaria in Thailand.
MALB2001 Completed A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Chemosuppressive Activity of a Fixed Dose Combination of Atovaquone/Proguanil (MALARONE) in Volunteers at Risk of Developing P. falciparum Malaria in Kenya
MALB2002 Completed Prophylactic Antimalarial Activity of Atovaquone in Volunteers Challenged with Plasmodium falciparum
MALB3001 Completed A Randomised, Double–Blind, Placebo–Controlled, Parallel Group Study to Evaluate the Suppressive Prophylactic Activity of MALARONE (atovaquone/proguanil) in Volunteers at Risk of Developing P. falciparum Malaria in Zambia
MALB3002 Completed An Open-Label Study to Evaluate the Safety and Efficacy of MALARONE (atovaquone/proguanil) as a Suppressive Prophylactic Agent Against Plasmodium falciparum Malaria in South Africa
MALB3003 Completed A Randomised, Double–Blind, Placebo–Controlled, Parallel Group Study to Evaluate the Suppressive Prophylactic Activity of MALARONE (atovaquone/proguanil) in Children at Risk of Developing Plasmodium falciparum Infection
MALB3005 Completed A Randomized, Double-Blind, Placebo-Controlled Trial of Malarone (Atovaquone 250mg and Proguanil Hydrochloride 100mg) Daily for Prophylaxis Against Plasmodium vivax and Plasmodium falciparum Infection in Javanese Transmigrants to Irian Jaya, Indonesia.
MALB3006 Completed An Open-Label Comparative Study to Determine the Safety and Efficacy of MALARONE (Atovaquone and Proguanil Hydrochloride) Versus Chloroquine in the Treatment of Acute Plasmodium falciparum Malaria in Children 5 and <11 kg in Weight in Nigeria
MD7108240 Completed A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration.
MD7110861 Completed An open-label, two-period, fixed-sequence study in Healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops
MD7111396 Completed An extension study to protocol MD7108240: pazopanib eye drops in subjects with neovascular age-related macular degeneration
MEE103219 Completed A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years (Study MEE103219) Study Listed on ClinicalStudyDataRequest.com
MEK111054 Completed An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects with Solid Tumors or Lymphoma
MET111516 Completed An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of two forms ofGSK1363089 in Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111643 Completed A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects with Metastatic Gastric Cancer Study Listed on ClinicalStudyDataRequest.com
MET111644 Completed A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects with Papillary Renal-Cell Carcinoma Study Listed on ClinicalStudyDataRequest.com
MET111646 Completed A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Study Listed on ClinicalStudyDataRequest.com
MET111647 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MET111648 Completed A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects with Solid Tumors Study Listed on ClinicalStudyDataRequest.com
MKC101614 Completed A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease.
MKI102428 Completed A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD) Study Listed on ClinicalStudyDataRequest.com
MKN106762 Completed A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.